Gastroprotection in patients prescribed non-selective NSAIDs, and the risk of related hospitalization

ABSTRACT

Objective: To assess co-prescription of gastroprotective agents (GPAs) for non-selective NSAID (nsNSAID)-treated patients in UK primary care, and the rate of gastrointestinal (GI)-related hospitalizations occurring with varying levels of GPA use in patients at high Gl risk.

Research design and methods: A retrospective, observational study was conducted using the DIN-LINK UK primary care database, on patients prescribed nsNSAIDs alone or concomitantly with GPAs between September 2003 and August 2005. Patients were stratified by GI risk, frequency of nsNSAID use and level of GPA use. Rates and odds ratios of GI-related hospitalizations were calculated for high GI–risk patients.

Results: In August 2005, 26 371 patients with nsNSAID prescriptions were identified, of whom 55% were frequent users. In the overall and frequent nsNSAID-user populations, 74% and 71%, respectively, were co-prescribed none or few GPAs (0–19% level of use), and only 18% and 20%, respectively, received complete gastroprotection. GI risk factors were identified in 76% of all patients. Overall, 70% of patients with serious co-morbidity, 44% with GI event history, and 56% of aspirin users received little or no gastroprotection (0–19%). Data for previous months of the analysis period were similar. In patients with a GI-event history, based on data over the 2-year study period, hospitalization rates ranged from 2.4% (with full gastroprotection) to 8.0% (20–39% GPA use). Odds of a GI-related hospitalization were up to 3.5 times higher with low GPA use.

Conclusion: This study revealed low levels of GPA co-prescription for nsNSAID users in UK primary care, even among high-risk patients. Lower levels of GPA co-therapy were associated with increasing rates of GI-related hospitalization.

Key words: :

• Gastroprotection
• NSAIDs
• Hospitalization
• Gastrointestinal

Acknowledgements

Declaration of interest: This study was sponsored by Pfizer Inc. T.A.K., S.P.L. and G.T.M. are full-time employees of Pfizer Inc. Editorial support for the preparation of this article was provided by C. Scarborough, PhD, of PAREXEL, and this assistance was funded by Pfizer Inc.